QuidelOrtho Corp
QDEL29.220USD
+0.320+1.11%
Handelsschluss 06/16, 16:00（ET）Kurse um 15 Minuten verzögert
1.97BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über QuidelOrtho Corp Unternehmen
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Unternehmensinformationen
BörsenkürzelQDEL
Name des UnternehmensQuidelOrtho Corp
IPO-datumFeb 01, 1991
Gegründet am2021
CEOMr. Brian J. Blaser
Anzahl der mitarbeiter6600
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 01
Addresse9975 Summers Ridge Road
StadtSAN DIEGO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18585521100
Websitehttps://www.quidelortho.com/
BörsenkürzelQDEL
IPO-datumFeb 01, 1991
Gegründet am2021
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
95.19K
+6.67%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
23.37K
+0.89%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
22.09K
+15.27%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
14.27K
+75.49%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
--
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
--
Ms. Evelyn S. Dilsaver
Ms. Evelyn S. Dilsaver
Independent Director
Independent Director
--
--
Mr. Lee Bowman
Mr. Lee Bowman
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
95.19K
+6.67%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
23.37K
+0.89%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
22.09K
+15.27%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
14.27K
+75.49%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Apr 6
Währung: USDAktualisiert: Sun, Apr 6
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Labs
1.43B
51.27%
Point-of-Care
694.10M
24.94%
Immunohematology
522.60M
18.78%
Donor Screening
115.50M
4.15%
Molecular Diagnostic Solutions
24.00M
0.86%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.57B
56.37%
Foreign
1.21B
43.63%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Labs
1.43B
51.27%
Point-of-Care
694.10M
24.94%
Immunohematology
522.60M
18.78%
Donor Screening
115.50M
4.15%
Molecular Diagnostic Solutions
24.00M
0.86%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
16.93%
BlackRock Institutional Trust Company, N.A.
11.17%
The Vanguard Group, Inc.
9.94%
Rubric Capital Management LP
9.08%
Invesco Advisers, Inc.
5.33%
Other
47.56%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
16.93%
BlackRock Institutional Trust Company, N.A.
11.17%
The Vanguard Group, Inc.
9.94%
Rubric Capital Management LP
9.08%
Invesco Advisers, Inc.
5.33%
Other
47.56%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
48.22%
Investment Advisor/Hedge Fund
41.40%
Hedge Fund
17.44%
Research Firm
2.15%
Pension Fund
1.27%
Sovereign Wealth Fund
1.18%
Individual Investor
0.88%
Bank and Trust
0.67%
Family Office
0.36%
Institutionelle Beteiligung
Aktualisiert: Tue, Mar 4
Aktualisiert: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
712
75.21M
111.49%
-13.46M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
2023Q1
894
68.68M
103.29%
-6.80M
2022Q4
939
69.19M
108.75%
-5.89M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
11.24M
16.66%
+1.84M
+19.59%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.79M
11.54%
+1.09M
+16.28%
Dec 31, 2024
The Vanguard Group, Inc.
6.80M
10.08%
-21.19K
-0.31%
Dec 31, 2024
Rubric Capital Management LP
5.55M
8.23%
+1.35M
+32.14%
Dec 31, 2024
Invesco Advisers, Inc.
3.23M
4.78%
+1.44M
+81.05%
Dec 31, 2024
AQR Capital Management, LLC
803.99K
1.19%
+539.98K
+204.53%
Dec 31, 2024
State Street Global Advisors (US)
2.27M
3.37%
+366.13K
+19.19%
Dec 31, 2024
ArrowMark Colorado Holdings, LLC
1.98M
2.93%
+100.52K
+5.35%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
1.22M
1.8%
+107.78K
+9.72%
Dec 31, 2024
American Century Investment Management, Inc.
1.12M
1.65%
+469.13K
+72.57%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Jun 6
Aktualisiert: Fri, Jun 6
Name
Anteil
SPDR S&P Health Care Equipment ETF
1.49%
Invesco S&P SmallCap Health Care ETF
1.39%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.69%
Ballast Small/Mid Cap ETF
0.37%
SPDR S&P 600 Small Cap Value ETF
0.34%
iShares S&P Small-Cap 600 Value ETF
0.34%
Avantis US Small Cap Value ETF
0.31%
WisdomTree US SmallCap Quality Growth Fund
0.3%
iShares U.S. Medical Devices ETF
0.24%
Avantis US Small Cap Equity ETF
0.22%
Mehr Anzeigen
SPDR S&P Health Care Equipment ETF
Anteil1.49%
Invesco S&P SmallCap Health Care ETF
Anteil1.39%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil0.69%
Ballast Small/Mid Cap ETF
Anteil0.37%
SPDR S&P 600 Small Cap Value ETF
Anteil0.34%
iShares S&P Small-Cap 600 Value ETF
Anteil0.34%
Avantis US Small Cap Value ETF
Anteil0.31%
WisdomTree US SmallCap Quality Growth Fund
Anteil0.3%
iShares U.S. Medical Devices ETF
Anteil0.24%
Avantis US Small Cap Equity ETF
Anteil0.22%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
